Comparison of the different doses of vancomycin on plasma concentration of the drug in patients hospitalized in ICU

Comparison of the different doses of vancomycin on plasma concentration of the drug in patients hospitalized in ICU: a double blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201710109014N194

Enrollment

Registered

2017-10-12

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Meningitis. Condition 2: Endocarditis. Condition 3: Sepsis. Condition 4: Osteomyelitis. Bacterial meningitis, not elsewhere classified Acute and subacute endocarditis Sepsis, unspecified Osteomyelitis

Interventions

Intervention 1: Intervention group 1: First injection of 1 g vancomycin as single dose and then 2 g per day for 2 weeks. Intervention 2: Intervention group 2: First injection of 1 gr vancomycin as sin

Treatment - Drugs

Intervention group 1: First injection of 1 g vancomycin as single dose and then 2 g per day for 2 weeks.

Intervention group 2: First injection of 1 gr vancomycin as single dose and then 15 mg/kg per day for 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18 to 60 years; meningitis or endocarditis or sepsis or osteomyelitis with positive culture for staph or enterococci resistant to methicillin. Exclusion criteria: Hypersensitivity to vancomycin; renal toxicity; using aminoglycoside drugs concurrently.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measuring plasma concentration of vancomycin. Timepoint: 2 months after treatment. Method of measurement: Through High Performance Liquid Chromatography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadali Salahshoor

School of Pharmacy

mohammadali.salahshoor@yahoo.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026